<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">69799</article-id><article-id pub-id-type="doi">10.7554/eLife.69799</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Quantifying chromosomal instability from intratumoral karyotype diversity using agent-based modeling and Bayesian inference</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-236093"><name><surname>Lynch</surname><given-names>Andrew R</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0238-682X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203982"><name><surname>Arp</surname><given-names>Nicholas L.</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8709-0667</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236365"><name><surname>Zhou</surname><given-names>Amber S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-132941"><name><surname>Weaver</surname><given-names>Beth A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7830-3816</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-89000"><name><surname>Burkard</surname><given-names>Mark E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4215-7722</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution content-type="dept">Carbone Cancer Center</institution>, <institution>University of Wisconsin-Madison</institution>, <addr-line><named-content content-type="city">Madison</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">McArdle Laboratory for Cancer Research</institution>, <institution>University of Wisconsin-Madison</institution>, <addr-line><named-content content-type="city">Madison</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-7131"><name><surname>Marston</surname><given-names>Adèle L</given-names></name><role>Reviewing editor</role><aff><institution>University of Edinburgh</institution>, <country>United Kingdom</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>mburkard@wisc.edu</email> (MB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>05</day><month>04</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e69799</elocation-id><history><date date-type="received"><day>27</day><month>04</month><year>2021</year></date><date date-type="accepted"><day>01</day><month>04</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Lynch et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Lynch et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-69799-v1.pdf"/><abstract><p>Chromosomal instability (CIN)-persistent chromosome gain or loss through abnormal mitotic segregation-is a hallmark of cancer that drives aneuploidy. Intrinsic chromosome mis-segregation rate, a measure of CIN, can inform prognosis and is a promising biomarker for response to anti-microtubule agents. However, existing methodologies to measure this rate are labor intensive, indirect, and confounded by selection against aneuploid cells, which reduces observable diversity. We developed a framework to measure CIN, accounting for karyotype selection, using simulations with various levels of CIN and models of selection. To identify the model parameters that best fit karyotype data from single-cell sequencing, we used approximate Bayesian computation to infer mis-segregation rates and karyotype selection. Experimental validation confirmed the extensive chromosome mis-segregation rates caused by the chemotherapy paclitaxel (18.5±0.5/division). Extending this approach to clinical samples revealed that inferred rates fell within direct observations of cancer cell lines. This work provides the necessary framework to quantify CIN in human tumors and develop it as a predictive biomarker.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01CA234904</award-id><principal-award-recipient><name><surname>Burkard</surname><given-names>Mark E</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01GM141068</award-id><principal-award-recipient><name><surname>Burkard</surname><given-names>Mark E</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30CA014520</award-id><principal-award-recipient><name><surname>Burkard</surname><given-names>Mark E</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>F31CA254247</award-id><principal-award-recipient><name><surname>Lynch</surname><given-names>Andrew R</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32HG002760</award-id><principal-award-recipient><name><surname>Lynch</surname><given-names>Andrew R</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32GM81061</award-id><principal-award-recipient><name><surname>Lynch</surname><given-names>Andrew R</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32GM008692</award-id><principal-award-recipient><name><surname>Arp</surname><given-names>Nicholas L.</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32GM008688</award-id><principal-award-recipient><name><surname>Zhou</surname><given-names>Amber S</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32GM140935</award-id><principal-award-recipient><name><surname>Arp</surname><given-names>Nicholas L.</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Mark E Burkard, declares the following:  Medical advisory board of Strata Oncology; Research funding from Abbvie, Genentech, Puma, Arcus, Apollomics, Loxo Oncology/Lilly, and Elevation Oncology.  I hold patents on microfluidic device for drug testing, and for homologous recombination and super-resolution microscopy technologies.I declare all interests without adjudicating relationship to the published work..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Single-cell DNA sequencing data from this study has been deposited in NCBI SRA (PRJNA725515). All data and scripts used for modeling and analysis have been deposited in OSF at https://osf.io/snrg3/.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Lynch AR</collab><collab>Arp NL</collab><collab>Zhou AS</collab><collab>Weaver BA</collab><collab>Burkard ME</collab></person-group><year iso-8601-date="2021">2021</year><source>Quantifying chromosomal instability from intratumoral karyotype diversity using agent- based modeling and Bayesian inference</source><ext-link ext-link-type="uri" xlink:href="https://osf.io/snrg3/">https://osf.io/snrg3/</ext-link><comment>Open-Science Framework, DOI: 10.17605/OSF.IO/SNRG3</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Lynch AR</collab><collab>Arp NL</collab><collab>Zhou AS</collab><collab>Weaver BA</collab><collab>Burkard ME</collab></person-group><year iso-8601-date="2021">2021</year><source>Quantifying chromosomal instability from intratumoral karyotype diversity Quantifying chromosomal instability from intratumoral karyotype diversity</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA725515">https://www.ncbi.nlm.nih.gov/bioproject/PRJNA725515</ext-link><comment>NCBI SRA, PRJNA725515</comment></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Bolhaqueiro ACF</collab><collab>Ponsioen B</collab><collab>Bakker B</collab><collab>Klaasen SJ</collab><collab>Kucukkose E</collab><collab>van Jaarsveld RH</collab><collab>Vivié J</collab><collab>Verlaan-Klink I</collab><collab>Hami N</collab><collab>Spierings DCJ</collab><collab>Sasaki N</collab><collab>Dutta D</collab><collab>Boj SF</collab><collab>Vries RGJ</collab><collab>Lansdorp PM</collab><collab>van de Wetering M</collab><collab>van Oudenaarden A</collab><collab>Clevers H</collab><collab>Kranenburg O</collab><collab>Foijer F</collab><collab>Snippert HJG &amp; Kops GJPL</collab></person-group><year iso-8601-date="2019">2019</year><source>Ongoing chromosomal instability and karyotype evolution in human colorectal cancer organoids</source><ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41588-019-0399-6#Sec24">https://www.nature.com/articles/s41588-019-0399-6#Sec24</ext-link><comment>Nature Genetics, 10.1038/s41588-019-0399-6</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-69799-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>